Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells

Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory. Valproic acid (VPA) has emerged as an anticancer drug via inhibition of histone deacetylases (HDACs), but the therapeutic advantages of a combination with V...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Chung Heon, Yoon, Wan Soo, Park, Kwang Ywel, Kim, Seong Muk, Lim, Jung Yeon, Woo, Ji Sun, Jeong, Chang Hyun, Hou, Yun, Jeun, Sin-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373250/
https://www.ncbi.nlm.nih.gov/pubmed/22701311
http://dx.doi.org/10.1155/2012/987495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373250/
https://www.ncbi.nlm.nih.gov/pubmed/22701311
http://dx.doi.org/10.1155/2012/987495

Ejemplares similares